Application of lysophosphatidic acid inhibitor in preparation of medicine for inhibiting PRRSV (porcine reproductive and respiratory syndrome virus) replication

By targeting the inhibitor HA130, the problem of difficult inhibition of PRRSV replication in the prior art was solved, which significantly reduced the viral load in pigs, relieved clinical symptoms, demonstrated the therapeutic effect of non-toxic and side effects, and for pigs, Reproductive and respiratory syndrome provides effective drug solutions.

CN118903116AActive Publication Date: 2024-11-08SUN YAT SEN UNIV

Patent Information

Application Number
CN202310506835.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-08
Publication Date
2024-11-08
Estimated Expiration
2043-05-08

AI Technical Summary

Technical Problem

The existing technology lacks effective drugs to inhibit the replication and transmission of pig reproduction and respiratory syndrome virus (PRRSV), resulting in huge economic losses in the pig breeding industry. The existing vaccine is not effective and there is a virulence that can be reinforcing the virus and wild. Risk of toxic recombination.

Method used

Through metabolomic analysis, it was found that the natural metabolite lysophosphatidic acid (LPA) has a promoting effect on PRRSV replication. The development of the targeted inhibitor HA130 can effectively inhibit the replication of PRRSV in pigs, relieve clinical symptoms and reduce viral load.

Benefits of technology

HA130 significantly reduced the viral load of PRRSV in pigs, relieved the symptoms caused by respiratory and reproductive syndrome, showed non-toxic and no side effects, and had good therapeutic potential and application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903116A_ABST
    Figure CN118903116A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and discloses application of a lysophosphatidic acid inhibitor in preparation of drugs for inhibiting PRRSV replication. Through analysis and screening of metabonomics, it is found that the natural metabolite lysophosphatidic acid LPA has a remarkable promoting effect on replication of PRRSV, LPA is inhibited in a targeted mode, replication of viruses in infected pigs can be effectively inhibited, clinical symptoms such as hyperpyrexia cough and the like caused by porcine respiratory and reproductive syndromes are relieved, and the application of the LPA in the preparation of porcine reproductive and respiratory syndromes is promoted. The virus load in virus infected tissues such as lung, spleen and inguinal lymph node is obviously reduced, and the pathological injury of the infected tissues is relieved. Therefore, the lysophosphatidic acid inhibitor has a good application prospect in the aspect of preventing and treating the porcine reproductive and respiratory syndrome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to the application of a lysophosphatidic acid inhibitor in the preparation of a drug for inhibiting PRRSV replication. Background Art

[0002] The pathogen of porcine reproductive and respiratory syndrome is porcine reproductive and respiratory syndrome virus (PRRSV). PRRSV belongs to the order Nidovirales and the family Arteriviridae. It is an enveloped, single-stranded positive-sense RNA virus. Pigs are the only host of PRRSV infection. Pregnant sows and piglets are most seriously infected, which can cause respiratory disorders and immune system suppression in pigs of all ages; pregnant sows have miscarriages, stillbirths, mummies, weak fetuses, etc.; piglets show symptoms such as diarrhea, swollen eyes, and paralysis of the limbs. Secondary infection leading to exhaustion is the main cause of death for piglets. It has caused huge economic losses to the pig farming industry at home and abroad.

[0003] Due to its biological characteristics such as high transmissibility, high variability and persistent infection, the prevention, control and elimination of PRRSV are relatively difficult. At present, there is no effective drug for the treatment of PRRS in clinical practice. The prevention and control of PRRSV mainly relies on purification and vaccine immunization. However, due to the development of the domestic pig industry and the limitations of breeding environment conditions, biosafety prevention and control, monitoring and purification conditions are still insufficient to face the threat of PRRSV transmission; on the other hand, the effect of commercial vaccines is not ideal, and the cross-protection ability of vaccines between different strains is poor. In addition, the process of live virus replication in pigs may cause the virus to become more virulent and recombine with wild viruses to form new strains. Therefore, the industry urgently needs a drug that can effectively inhibit and eliminate PRRSV. Summary of the invention

[0004] The purpose of the present invention is to overcome the shortcomings and defects of the prior art and provide the use of a lysophosphatidic acid inhibitor in the preparation of a drug for inhibiting PRRSV replication.

[0005] The purpose of the present invention is achieved through the following technical solutions: the use of lysophosphatidic acid inhibitors in the preparation of drugs for inhibiting PRRSV replication is based on the fact that the inventors of the present invention found through metabolomics analysis and screening that the natural metabolite lysophosphatidic acid (LPA) has a significant promoting effect on the replication of PRRSV. Targeted inhibition of LPA can effectively inhibit viral replication in infected pigs, alleviate clinical symptoms such as high fever and cough caused by porcine respiratory and reproductive syndrome, significantly reduce the viral load in virus-infected tissues such as the lungs, spleen, and inguinal lymph nodes, and reduce pathological damage to infected tissues.

[0006] The lysophosphatidic acid inhibitor is preferably HA130 having the structural formula shown in (1);

[0007]

[0008] The drug for inhibiting PRRSV replication is a drug for antagonizing porcine reproductive and respiratory syndrome virus replication, which can target and down-regulate the LPA level, antagonize the replication of PRRSV, and alleviate the symptoms of porcine reproductive and respiratory syndrome.

[0009] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0010] (1) The present invention discovered for the first time that the natural metabolite lysophosphatidic acid (LPA) has a significant promoting effect on the replication of PRRSV. Targeted inhibition of LPA can effectively inhibit the replication of the virus in infected pigs, alleviate clinical symptoms such as high fever and cough caused by porcine respiratory and reproductive syndrome, significantly reduce the viral load in virus-infected tissues such as the lungs, spleen, and inguinal lymph nodes, and alleviate pathological damage to infected tissues.

[0011] (2) The present invention discloses for the first time that HA130 has anti-PRRSV activity, and HA130 is used to successfully inhibit PRRSV replication in a permissible porcine alveolar macrophage cell line (iPAMs), and is dose-dependent, showing the potential of HA130 in treating PRRSV. Furthermore, in the piglet treatment experiment, HA130, as a natural metabolite molecule, showed the advantages of being non-toxic and having no side effects in the control group; in the infected piglets, HA130 treatment significantly alleviated the piglets' symptoms of fever, cough, and anorexia; and HA130 treatment greatly reduced the viral load in the lungs, spleen, and inguinal lymph nodes of the infected piglets, and reduced tissue damage in the lungs and spleen. HA130 shows great potential as a PRRSV therapeutic drug, and its targeted natural metabolite molecule has a clear structure, is easy to prepare, is non-toxic, and has no side effects, and has a good application prospect in the prevention and treatment of porcine reproductive and respiratory syndrome. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 The non-targeted metabolome and non-targeted lipidome analysis results of pig sera infected and uninfected with PRRSV at 3, 7, 10, and 21 days. A is the serum metabolome model establishment and analysis process; B is the volcano diagram of differential metabolites in the serum metabolome at 3, 7, 10, and 21 dpi (days post infection), with the horizontal axis being log2 (foldchange) and the vertical axis being log 10(q value), differential metabolites were screened out under the condition of metabolite fold change ≥ 1.2 or ≤ 0.8 and q value < 0.05. The blue and red dots are the metabolite molecules that are significantly up- and down-regulated, respectively; C is the volcano plot of differential metabolites in serum lipid groups at 3, 7, 10, and 21 dpi, with the horizontal axis being log2 (fold change) and the vertical axis being log 10 (qvalue), differential lipid molecules were screened out based on the conditions of metabolite fold change ≥ 1.2 or ≤ 0.83 and q value < 0.05. The blue and red dots are the lipid molecules that are significantly up- and down-regulated, respectively; D is the heat map of the expression changes of all differential metabolites and lipid molecules in pig serum at 3, 7, 10, and 21 dpi. Each row is a significantly changed differential molecule, blue is down-regulated, and red is up-regulated.

[0013] Figure 2 The results of the effect of HA130 on PRRSV in iPAMs are shown in Figure 1. A is the cytotoxicity test results of LPA and HA130 on iPAMs; B is the WB test of the effect of different concentrations of LPA on PRRSV replication and the grayscale scanning results; C is the WB test of the effect of different concentrations of HA130 on PRRSV replication and the grayscale scanning results; D is TCID 50 Detect the effect of different concentrations of LPA on virus titer; E is TCID 50 The effects of different concentrations of HA130 on virus titer were detected. The results showed that HA130 had an inhibitory effect on PRRSV in iPAMs in a dose-dependent manner.

[0014] Figure 3 It is a graph showing the statistics of piglet treatment experiment data and viral load measurement results; among them, A is the piglet temperature monitoring result; B is the piglet serum LPA concentration; C is the viral load detection of piglet lung tissue in the challenge group and the challenge treatment group; D is the viral load detection of piglet spleen in the challenge group and the challenge treatment group; E is the viral load detection of piglet inguinal lymph nodes in the challenge group and the challenge treatment group.

[0015] Figure 4 This is a photograph of the results of histopathological sections of piglet treatment experiments. DETAILED DESCRIPTION

[0016] The present invention will be described in further detail below in conjunction with the embodiments and accompanying drawings.

[0017] The experimental process of the present invention is summarized as follows: First, the obtained PRRSV positive and negative sera are subjected to metabolomics mass spectrometry detection, and the metabolomics data are analyzed by bioinformatics methods, and a significantly upregulated metabolic molecule, lysophosphatidic acid (LPA), is screened. Its level is highly positively correlated with the viral load of PRRSV, and may play an important role in the infection and replication process of PRRSV. Therefore, the present invention verifies the promoting effect of LPA on PRRSV replication in a substitutable porcine alveolar macrophage cell line (iPAMs), and selects the drug HA130 that targets and inhibits LPA to determine its inhibitory effect on PRRSV replication. Finally, an animal experiment is carried out to treat piglets infected with PRRSV with medication to test the clinical therapeutic effect of HA130.

[0018] The materials used in this experiment are as follows:

[0019] (1) Cells and viruses

[0020] The highly pathogenic PRRSV strain Li11, African green monkey embryonic kidney cells Marc-145, and immortalized porcine alveolar macrophages (iPAMs) are maintained by this laboratory. The strains and cells are conventional strains and cells that have been disclosed in the prior art (see "Wei Y, et al. Porcine TRIM21RING-finger E3 ubiquitin ligase is essential for anti-PRRSV activity. Veterinary Microbiology 256 (2021)").

[0021] (2) Main reagents

[0022] LPA used for in vitro experiments was purchased from Avanti Polar Lipids, and HA130 used for in vivo and in vitro experiments was purchased from MedChemExpress; the enhanced CCK8 kit was purchased from Beyotime Biotechnology Co., Ltd.; the antibody against PRRSVN protein (JN-0401) was purchased from Jinnuo Diagnostics of Korea; the internal reference GAPDH mouse monoclonal antibody and goat anti-mouse secondary antibody were purchased from Abcam; the reverse transcription reagent PrimeScriptTM RT Master Mix was purchased from Taraka, PerfectStart Green qPCR SuperMix was purchased from Quanshijin Company, and the LPA ELISA detection kit was purchased from Signalway Antibody (SAB); other conventional reagents were of analytical grade.

[0023] Example 1

[0024] Ten pigs were divided into a control group (5 pigs) and a challenge group (pigs). The highly pathogenic PRRSV strain Li11 was used for challenge. Pig serum was collected 3, 7, 10, and 21 days after challenge for non-targeted metabolomics and non-targeted lipidomics testing. The results are as follows: Figure 1 As shown, a significantly upregulated metabolic molecule, lysophosphatidic acid (LPA), was screened out. Its level was highly positively correlated with the viral load of PRRSV, and may play an important role in the infection and replication process of PRRSV.

[0025] Example 2

[0026] Effects of LPA and its inhibitor HA130 on PRRSV replication in iPAMs

[0027] (1) Cytotoxicity test of LPA and HA130 on iPAMs

[0028] The CCK8 cytotoxicity assay was used to determine the cytotoxicity of LPA and HA130 on iPAMs as follows:

[0029] 6 × 10 5 Cell suspension (100 μL / well) of 10 cells / mL was added, and one column was left uninoculated. Cultured at 37°C and 5% CO2 until the cells were fully confluent. The culture medium was aspirated, washed 3 times with PBS, and LPA was diluted to different concentrations (5μM, 10μM, 20μM, 50μM, 100μM, 500μM) with RPMI-1640 culture medium, with 3 replicates for each concentration, 100 μL / well. After 48h of culture at 37°C and 5% CO2, the drug solution was aspirated, washed 3 times with PBS, and 10% (v / v) CCK8 solution was prepared with RPMI-1640 culture medium and added to a 96-well plate (100 μL / well), incubated at 37°C and 5% CO2 for 1h, and the absorbance value (λ=450nm) was measured with an enzyme marker and the cell viability after 48h of treatment with different concentrations of drug solution was calculated.

[0030] Similarly, HA130 was dissolved in DMSO and diluted to different concentrations (10nM, 50nM, 100nM, 200nM, 500nM, 1000nM), with 3 replicates for each concentration, 100μL / well. After culturing at 37°C, 5% CO2 for 48h, the drug solution was aspirated, washed 3 times with PBS, and 10% CCK8 solution was prepared with RPMI-1640 medium and added to 96-well plates (100μL / well), incubated at 37°C, 5% CO2 for 1h, and the absorbance value (λ=450nm) was measured with an enzyme marker and the cell viability after 48h treatment with different concentrations of drug solution was calculated.

[0031] The results are as follows Figure 2As shown in A, the maximum safe concentration of LPA for iPAMs is 100 μM, and the maximum safe concentration of HA130 is 200 nM.

[0032] (2) Effects of LPA and HA130 on PRRSV replication in iPAMs—western blot

[0033] 6 × 10 5 1 mL of cell suspension was inoculated at a cell concentration of 1 cell / mL, and cultured at 37°C, 5% CO2 until the cells were fully confluent. The culture medium in the 6-well plate was discarded and washed 3 times with PBS. 1640 culture medium with LPA concentrations of 0 μM (negative control), 0 μM (positive control), 25 μM, 50 μM, and 100 μM was added to the 5 wells with cells to treat the cells for 1 hour, the treatment solution was discarded, and PRRSV virus solution (MOI = 0.1) was added to the wells except the negative control. After infection for 1 hour, the supernatant was discarded, and the 1640 culture medium containing 2% (v / v) FBS was replaced after washing 3 times with PBS, and cultured at 37°C, 5% CO2 for 24 hours.

[0034] The treatment solution was discarded, and the cells were washed three times with PBS. 200 μL of RIPA lysis buffer was added to each well, and the cells were lysed on ice for 10 min. The cell pellets were mixed by pipetting and transferred to 1.5 mL sterile EP tubes, and centrifuged at 12000 r / min for 5 min. 180 μL of supernatant was aspirated and mixed with 36 μL of 5× loading buffer (5 times the concentration of loading buffer), and the protein samples of western blot were obtained by water bath at 100°C for 10 min.

[0035] The protein samples were obtained by the same method after pre-treatment with 0 nM (negative control), 0 nM (positive control), 50 nM, 100 nM, and 200 nM HA130 and infection with PRRSV (MOI=0.1) for 24 h.

[0036] Use 10-well, 10% precast gel for electrophoresis, and the loading order is: Marker, 0μM (negative control), 0μM (positive control), 25μM, 50μM, 100μM LPA treated samples. The electrophoresis instrument program is set to 80V electrophoresis for 30min and 120V electrophoresis for 1h. After the electrophoresis, use a semi-dry transfer system to assemble the transfer system. The assembly order is: black side (negative electrode) - sponge - filter paper - protein gel - PVDF membrane - filter paper - sponge - white side (positive electrode). After assembly, use a clean test tube or glass rod to remove bubbles. The transfer instrument program is set to 15V transfer for 40min. After the transfer, take out the PVDF membrane, wash it with TBST for 5min, and place it in 5% skim milk powder for blocking at room temperature for 1h.

[0037] Pour off the blocking solution and wash three times with TBST, 5 minutes each time. Then take out the membrane and wrap it with clean plastic wrap, cut off the membrane where the 15kDa PRRSV-N protein and 36kDa GAPDH are located and place it in the corresponding primary antibody, and incubate it on a shaker at 40r / min and 4°C overnight. After the incubation, recover the primary antibody and wash it three times with TBST, 5 minutes each time. Place the two membranes in the HRP-labeled goat anti-mouse IgG secondary antibody solution diluted with TBST (dilution ratio 1:10000), place it on a shaker, 40r / min, and incubate at room temperature for 1h. Recover the secondary antibody dilution, wash the membrane with TBST 3 times, 5 minutes each time, soak the membrane in TBST, prepare the ECL colorimetric solution under light-proof conditions, and use a gel scanning system to develop and take pictures.

[0038] The same method was used to detect the PRRSV-N protein and GAPDH bands of samples pretreated with 0 nM (negative control), 0 nM (positive control), 50 nM, 100 nM, and 200 nM HA130.

[0039] The results are as follows Figure 2 As shown in B and C in Figure 1, the proliferation of PRRSV virus after LPA and HA130 treatment was detected by Western blotting (WB): after LPA treatment, the color of the corresponding PRRSV-N protein-sized band gradually increased with the increase of drug concentration; while after HA130 treatment, the PRRSV-N protein content gradually decreased with the increase of drug concentration. This shows that LPA promotes the proliferation of PRRSV, while its inhibitor HA130 can inhibit the replication of PRRSV, and both are dose-dependent.

[0040] (3) Effects of LPA and HA130 on PRRSV replication in iPAMs—TCID 50

[0041] 6 × 10 51 mL of cells were inoculated into each well at a cell concentration of 1 cell / mL. 1640 medium with LPA concentrations of 0 μM (negative control), 0 μM (positive control), 25 μM, 50 μM, and 100 μM was added to 5 wells with cells respectively; HA130 dissolved in DMSO was added to the other 5 wells with cells respectively, so that the concentrations of HA130 were 0 nM (negative control), 0 nM (positive control), 50 nM, 100 nM, and 200 nM, and the treatment solution was discarded after 1 hour of drug treatment. PRRSV virus solution (MOI = 0.1) was added to the wells except the negative control, and the supernatant was discarded after 1 hour of infection. After washing 3 times with PBS, the 1640 medium containing 2% (v / v) FBS was replaced and cultured at 37°C and 5% CO2 for 24 hours. The cell culture plate was taken out and sealed with sealing film, and then frozen and thawed at -80°C for 3 times. The culture after freezing and thawing was collected into a sterile 1.5mL EP tube, placed in a high-speed centrifuge at 10000r / min, and centrifuged at 4°C for 5min. The supernatant was collected into a new 1.5mL EP tube and stored at -80°C.

[0042] Press 6×10 5 Cells were seeded in 5 96-well plates at a concentration of 100 μL per well and cultured at 37°C and 5% CO2 until the cells were fully confluent. The 96-well plates with cells were washed 3 times with PBS and the collected samples were diluted 10-fold to 0-10 -7 8 gradients, add the diluted samples into the cell wells of the corresponding dilution multiples, repeat 8 wells for each gradient, 100 μL per well, and culture at 37°C, 5% CO2 for 5 to 7 days.

[0043] The number of lesion wells in each dilution gradient was observed and recorded under a microscope, and the viral titer of PRRSV infection 24 hours after iPAMs were treated with different concentrations of LPA and its inhibitor HA130 was calculated using the Reed-Muench method.

[0044] The results are as follows Figure 2 As shown in D and E, after LPA treatment of iPAMs, the viral titer of PRRSV was higher at 24 h of infection, while HA130 treatment was able to reduce the viral titer of PRRSV, and both were dose-dependent.

[0045] Example 3

[0046] The therapeutic effect of HA130 on piglets infected with PRRSV

[0047] (1) Design of piglet treatment experiment

[0048] 48 commercial piglets (Large White pigs, purchased from Wen's Food Group Co., Ltd.) aged 4 weeks were tested by ELISA and PCR, and the antibodies and antigens of PRRSV, PCV2, PRV and CSFV were all negative. They were randomly divided into 4 groups (12 pigs in each group), specifically:

[0049] The first group was the blank control group, in which each pig was injected with an equal volume of DMEM to the challenge dose, and the drug-treated group was injected with an equal volume of empty solvent (10% DMSO + 40% PEG3000 + 5% Tween-80 + 45% saline) at the beginning of treatment;

[0050] The second group was the drug-administered control group, in which each pig was injected with an equal volume of DMEM to the challenge dose and an equal volume of HA130 solution during the treatment phase;

[0051] The third group was the challenge group, and each pig was intramuscularly injected with 2 mL of a titer of 1×10 -6 The highly pathogenic strain Li11 virus solution of PRRSV with TCID50 / ml was injected with an equal volume of empty solvent (10% DMSO + 40% PEG3000 + 5% Tween-80 + 45% saline) during treatment in the drug-treated group;

[0052] The fourth group was the challenge treatment group, and each pig was injected intramuscularly with 2 mL of a titer of 1x10 -6 The highly pathogenic strain of PRRSV Li11 virus liquid with TCID50 / ml was injected intramuscularly with HA130 solution at a dose of 1 mg / kg body weight every day for three consecutive days, starting when the pig's body temperature was detected to be elevated with obvious fever symptoms.

[0053] HA130 solution formula: 10% DMSO + 40% PEG3000 + 5% Tween-80 + 45% saline + HA130.

[0054] Experiment and sampling arrangements:

[0055] After the piglets were transported to the disinfected experimental site, they were randomly divided into 4 groups and placed in different sites. They were allowed to freely drink water and eat for 2 days to adapt to the environment. On the 3rd day, the third and fourth groups were injected intramuscularly with the virus, and the first and second groups were injected with an equal volume of DMEM. After the virus attack, the rectal temperature of the piglets was monitored daily. When the third and fourth groups of piglets showed high fever symptoms (≥40°C), HA130 treatment was started. The first and second groups of piglets were injected intramuscularly with 1 mg / kg body weight of HA130 solution for three consecutive days. The rectal temperature and clinical symptoms of each group of piglets were continuously monitored, including body weight, skin, eating habits, mental state, etc.;

[0056] At 1, 3, 5, and 7 days after the end of administration, piglet serum was collected to detect changes in lysophosphatidic acid levels. Three piglets were randomly selected from each group and killed to collect lung, spleen, and inguinal lymph node samples, three tissues susceptible to PRRSV infection and pathological changes, to measure the viral load and examine the tissue pathology.

[0057] (2) Clinical symptoms

[0058] No piglets died during the experiment. The results of temperature monitoring were as follows: Figure 3 As shown in A, on the second day after the challenge, the third and fourth groups of piglets injected with PRRSV virus solution all showed high fever symptoms (≥40°C), so the control group and the challenge treatment group were treated with HA130 on the 2nd to 4th day after the challenge, and the other two groups were injected with an equal volume of solvent. The results showed that HA130 administration reduced the high fever symptoms of the piglets in the treatment group. On the third day after the start of administration, the body temperature of the piglets in the treatment group had dropped below 40.5°C and tended to normal body temperature.

[0059] (3) Serum LPA content detection

[0060] Piglet serum was collected on days 1, 3, 5, and 7 after administration, and serum LPA content was detected using the SAB LPA ELISA Kit as follows:

[0061] Use sample diluent to dissolve the LPA standard provided by the kit, and dilute it step by step to seven concentration gradients of 4000pg / mL, 2000pg / mL, 1000pg / mL, 500pg / mL, 250pg / mL, 125pg / mL, and 62.5pg / mL. Set up blank wells in a 96-well plate, add gradient concentration standards and serum samples in sequence, 50μL per well, then add 50μL HRP-Conjugate to each well except the blank well, tap gently to mix, cover with film, and incubate at 37°C for 1h; discard the solution, add 250μL wash buffer to each well, let it stand for 1min, then absorb it, repeat the washing 5 times, and after the last wash, turn the well plate upside down on absorbent paper and let it stand for 3min; add 100μL Substrate to each well except the blank well Solution (substrate solution), incubate in the dark at 37°C for 20 minutes. When the high-concentration standard in the first 3 wells turns obviously blue, add 50 μL Stop Solution (stop buffer) to each well, use a microplate reader to measure the absorbance at 450 nm, draw a standard curve and calculate the LPA concentration in the sample wells.

[0062] The results are as follows Figure 3As shown in B, the LPA level in the PRRSV infection group was consistent with the metabolomics results. PRRSV infection upregulated the host serum LPA content, while HA130 treatment effectively reduced the serum LPA content, causing the serum LPA content of PRRSV-infected piglets to return to normal levels.

[0063] (4) Viral load testing of lung, spleen, and inguinal lymph node tissue samples

[0064] Three piglets were randomly selected from each group at 1, 3, 5, and 7 days after the end of the administration, and samples of lung, spleen, and inguinal lymph nodes, three tissues susceptible to PRRSV infection and pathological changes, were collected. The expression level of PRRSV-N mRNA was determined by qRT-PCR, as follows:

[0065] After the tissue was thawed, about 1g of tissue sample was transferred to a special tube for tissue crusher, 1mL Trizol was added, sterilized ceramic beads were added and placed in a tissue crusher, and the tube was violently shaken for 3 times, 20s / time, and then placed on ice for lysis for 20min; centrifuged at 12000rpm for 5min, the supernatant was transferred to a clean RNase-free EP tube, 200μL chloroform was added, vortexed violently, and after standing for stratification, centrifuged at 12000rpm for 10min; the supernatant was transferred to a new RNase-free EP tube, an equal volume of isopropanol was added, mixed, and precipitated at -20℃ for 1h; centrifuged at 12000rpm for 15min, the supernatant was discarded, and RNA precipitate was obtained; rinsed with 75% alcohol twice, air-dried for 5min, 50μL RNase-free water was added for dissolution, and the concentration and OD value were determined. Reverse transcription was performed according to the instructions of Taraka's PrimeScriptTM RT Master Mix (Perfect Real Time). The reverse transcription system was: 2 μL 5× PrimeScript RT Master Mix, 500 ng total RNA, and finally RNase Free ddH2O was added to 10 μL. After thorough mixing, reverse transcription was performed on a PCR instrument. The reaction program was: 37°C for 15 min; 85°C for 5 s. The product was frozen at -80°C and stored for later use.

[0066] Using the above cDNA as a template, real-time fluorescence quantitative PCR was used to detect the expression levels of PRRSV-N and GAPDH mRNA in tissue samples. The primer sequences are as follows:

[0067] PRRSV-NF: 5'-TAAGATCATCGCCCAACAAA-3'

[0068] PRRSV-NR: 5'-TCGGCAAACTAAACTCCACA-3';

[0069] GAPDH-F: 5'-CCTTCCGTGTCCCTACTGCCAAC-3'

[0070] GAPDH-R: 5'-GACGCCTGCTTCACCACCTTCT-3'.

[0071] The PCR reaction was carried out according to the instructions of PerfectStart Green qPCR SuperMix of Quanshijin Company. The reaction system was: 1μL cDNA, 5μL 2×PerfectStart Green qPCR SuperMix, 0.2μL PassiveReference Dye (50×), 0.2μL of 10μM upstream and downstream primers, and 3.4μL RNase Free water. The system was prepared according to the amount of 3 replicates for each sample, and 10μL was added to each well of a 384-well plate. The reaction was carried out on an ABI 7300 Real time PCR instrument. The reaction program was: pre-denaturation at 95℃ for 2min; 95℃ for 15s, 61℃ for 31min, for a total of 40 cycles. According to the CT value, 2 -ΔΔCT The expression levels of PRRSV-N and GAPDH mRNA in each tissue sample were calculated by the method.

[0072] The results are as follows Figure 3 As shown in Figures C, D, and E, compared with the challenge group, the PRRSV-N mRNA levels in the lungs, spleen, and inguinal lymph nodes of piglets after HA130 treatment were significantly reduced, indicating that HA130 has the effect of inhibiting PRRSV replication in vivo.

[0073] (5) Histopathological changes

[0074] Remove a small piece of tissue no larger than 4 mm × 2 cm from the collected lungs, spleen, and inguinal lymph nodes. 2 The tissue blocks were fixed with 4% paraformaldehyde, dehydrated with alcohol gradient, transparentized with xylene, embedded in paraffin, trimmed, sliced, and stained with hematoxylin and eosin. The lung tissue sections were observed under a microscope.

[0075] The results are as follows Figure 4As shown: There were no lesions in the lung, spleen, and inguinal lymph node tissue sections of the drug-treated control group, indicating that HA130 had no significant effect on host organs; compared with the Mock control group, a large number of red blood cells were seen between the cells beside the blood vessels in the lung tissue sections of the virus-challenged group, which was a diffuse bleeding phenomenon after infection, and alveolar hypertrophy, alveolar wall epithelial macrophage hyperplasia, alveolar septum thickening, inflammatory cell infiltration, spleen tissue hemorrhage and other characteristic pathological phenomena of porcine reproductive and respiratory syndrome were observed; while there were no obvious bleeding spots around the blood vessels of the lung tissue of the virus-challenged treatment group, the alveolar wall and alveolar size were also normal, and there was no obvious bleeding in the spleen of the treatment group; there was no significant difference in the inguinal lymph nodes among the groups. These results show that HA130 treatment effectively reduced the damage of PRRSV to tissues.

[0076] The above-mentioned embodiments only express a few of the many implementation methods of the present invention. Although the description is relatively specific and detailed, it cannot be understood as limiting the scope of the present invention. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. Application of lysophosphatidic acid inhibitors in the preparation of drugs for inhibiting PRRSV replication.

2. The use of a lysophosphatidic acid inhibitor in the preparation of a drug for inhibiting PRRSV replication, characterized in that: The lysophosphatidic acid inhibitor is HA130.

Citation Information

Patent Citations

  • The invention also discloses application of glycolysis inhibitor in preparation of medicines for preventing and treating porcine reproductive and respiratory syndrome virus infection

    CN111803634A

  • Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

    US20170157048A1

  • Diagnostic and therapeutic method involving the autotaxin-lysophosphatidic acid signalling pathway

    WO2015193669A1

  • Vaccine composition for preventing porcine reproductive and respiratory syndrome, preparation method therefor and use thereof

    WO2018000722A1

Cited By

  • Application of lysophosphatidylcholine and dihydromyricetin in preparation of medicine for treating or preventing porcine reproductive and respiratory syndrome virus infection

    CN120837507A

  • Application of phosphatidylcholine in preparation of medicine for preventing and treating porcine rotavirus infection

    CN122097390A